

- **Name:** Myung Ah Lee
Chief of Medical Oncology,
Director of Colorectal cancer center, ,
 - **Current Position & Affiliation:** **Chief of IRB panel V,**
Seoul St. Mary's hospital, Catholic
University
 - **Country:** **Korea**
-

• Educational Background:

- Mar, 1988-Feb, 1994 Medical College, Catholic University of Korea
- Mar. 1994-Feb. 1995 Internship in Our lady of Mercy Hospital, Catholic University of Korea
- Mar, 1996-Feb. 2000 Residency of Internal Medicine in Kangnam St. Mary's Hospital, Catholic University of Korea
- Sep, 1999-Aug. 2000 Master's degree, Graduate school of Medicine, Catholic University of Korea
- Mar. 2000-Feb, 2001 Clinical Fellow, Division of Hemato-oncology, Catholic Hematopoietic stem cell transplantation center, St. Mary's Hospital, Catholic University of Korea
- Mar, 2004- Feb, 2007 Ph. D, Graduate school of Medicine, Catholic University of Korea

• Professional Experience:

- Mar. 2002- Mar, 2005 Instructor, Division of Hemato-oncology, Department of Internal Medicine, Kangnam St. Mary's Hospital, Catholic University of Korea
- Apr, 2005- Mar, 2009 Assistant Professor, Division of Hemato-oncology, Kangnam St. Mary's Hospital, Catholic University of Korea
- Jul, 2007-Dec, 2008 Research fellow, Cell & developmental biology Weil Medical College of Cornell University, NY, USA
- Apr, 2009- Mar, 2014 Associate Professor, Division of Hemato-oncology, Seoul St. Mary's Hospital, Catholic University of Korea
- Apr, 2014- at present Professor / Chief of Medical Oncology Department of Internal Medicine, Seoul St. Mary's Hospital Catholic University of Korea

• Professional Organizations:

The Korean Cancer Association, member of board director
The Korean Cancer Association, Associate Editor of editorial board committee
The Korean Society of Medical Oncology, Director of Publication Committee
The Korean Society for Hospice and Palliative care, Director of Regulation
The Korean Society for Hospice and Palliative care, Editorial Committee
The Korean Cancer Study Group, Hepato-biliary-pancreatic cancer Committee
The Korean Cancer Study Group, Colorectal cancer Committee
The Korean Cancer Study Group, Protocol Review Committee
The Korean Association of Internal Medicine, member of Hemato-Oncology subspecialty Board Committee
The Korean Association IRB, information Committee
Health Insurance Review & Assessment Service, advisory Committee
The Ministry of Food and Drug Safety, Pharmaceutical Safety Bureau
Active member, The American Society of Clinical Oncology
Active member The American Association for Cancer Research
Active member, The European Society of Medical Oncology
Active member, The Korean Association of Internal Medicine
Active member, The Korean Medical Association
Active member, The Korean Liver Cancer Association

• Main Scientific Publications:

- 1) Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial. *JAMA Oncol* 2020
- 2) Oral chemotherapy for 2nd-line treatment in patients with gemcitabine-refractory advanced pancreatic cancer *World J Gastrointest Oncol* 2019
- 3) Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as 1st line therapy for advanced biliary tract cancer: a multicenter, open label, randomized, phase III, noninferiority trial. *Ann Oncol* 2019
- 4) β -Catenin expression is associated with cell invasiveness in pancreatic cancer *Korean J Intern Med* 2019
- 5) Phase I Dose-Finding Study of OPB-111077, a Novel STAT3 Inhibitor, in Patients with Advanced Hepatocellular Carcinoma *Cancer Res Treat* 2019

and over 100 since 2002